Literature DB >> 19702735

Refractory seizures: try additional antiepileptic drugs (after two have failed) or go directly to early surgery evaluation?

Patrick Kwan1, Michael R Sperling.   

Abstract

The goal of antiepileptic therapy is to achieve long-term seizure freedom with minimal or no adverse effects. Current evidence suggests that in many patients who have failed two appropriate antiepileptic drugs (AEDs) because of lack of efficacy, the chance of subsequent seizure freedom with further drug manipulation is low (reports ranging from as little as a few percent to nearly one-fourth of patients). Achieving this may require repeated drug manipulations. Surgery, in appropriately selected candidates, may render up to 70% of patients seizure-free when temporal resection is done, although frontal resection may have only a 25% yield. Both courses of actions (further drug trials and surgery) are associated with a plethora of potential adverse outcomes. Therefore, it is recommended that such patients be promptly referred to an epilepsy center for a comprehensive review of the diagnosis and management, which may include initial evaluation for surgery. Because presurgical evaluation and surgery itself may entail discomfort and risk, the decision to offer surgical treatment requires individual risk-benefit analysis that includes an assessment of possible success with additional trials of medication.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19702735     DOI: 10.1111/j.1528-1167.2009.02237.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  22 in total

1.  Non-rigid registration with missing correspondences in preoperative and postresection brain images.

Authors:  Nicha Chitphakdithai; James S Duncan
Journal:  Med Image Comput Comput Assist Interv       Date:  2010

2.  Epilepsy surgery trends in the United States, 1990-2008.

Authors:  D J Englot; D Ouyang; P A Garcia; N M Barbaro; E F Chang
Journal:  Neurology       Date:  2012-03-21       Impact factor: 9.910

Review 3.  Deep brain stimulation for the treatment of epilepsy: circuits, targets, and trials.

Authors:  Nealen G Laxpati; Willard S Kasoff; Robert E Gross
Journal:  Neurotherapeutics       Date:  2014-07       Impact factor: 7.620

4.  Increased GABAergic inhibition in the midline thalamus affects signaling and seizure spread in the hippocampus-prefrontal cortex pathway.

Authors:  David M Sloan; DeXing Zhang; Edward H Bertram
Journal:  Epilepsia       Date:  2011-01-04       Impact factor: 5.864

5.  Improved Detection of Subtle Mesial Temporal Sclerosis: Validation of a Commercially Available Software for Automated Segmentation of Hippocampal Volume.

Authors:  J M Mettenburg; B F Branstetter; C A Wiley; P Lee; R M Richardson
Journal:  AJNR Am J Neuroradiol       Date:  2019-02-07       Impact factor: 3.825

6.  Quantitative analysis of structural neuroimaging of mesial temporal lobe epilepsy.

Authors:  Negar Memarian; Paul M Thompson; Jerome Engel; Richard J Staba
Journal:  Imaging Med       Date:  2013-06-01

7.  Virtual resection predicts surgical outcome for drug-resistant epilepsy.

Authors:  Lohith G Kini; John M Bernabei; Fadi Mikhail; Peter Hadar; Preya Shah; Ankit N Khambhati; Kelly Oechsel; Ryan Archer; Jacqueline Boccanfuso; Erin Conrad; Russell T Shinohara; Joel M Stein; Sandhitsu Das; Ammar Kheder; Timothy H Lucas; Kathryn A Davis; Danielle S Bassett; Brian Litt
Journal:  Brain       Date:  2019-12-01       Impact factor: 13.501

Review 8.  Possible alterations in GABAA receptor signaling that underlie benzodiazepine-resistant seizures.

Authors:  Tarek Z Deeb; Jamie Maguire; Stephen J Moss
Journal:  Epilepsia       Date:  2012-12       Impact factor: 5.864

Review 9.  Seizure outcomes in nonresective epilepsy surgery: an update.

Authors:  Dario J Englot; Harjus Birk; Edward F Chang
Journal:  Neurosurg Rev       Date:  2016-05-21       Impact factor: 3.042

Review 10.  Rates and predictors of seizure freedom in resective epilepsy surgery: an update.

Authors:  Dario J Englot; Edward F Chang
Journal:  Neurosurg Rev       Date:  2014-02-05       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.